2 results
Approved WMOCompleted
The objectives of this study are to assess the efficacy, safety, and tolerability of a once daily oral dose of laquinimod (0.6 or 1.5 mg) compared to placebo in PPMS patients.
Approved WMOCompleted
Objective: to provide an answer to the following question: in patients with AD, does treatment with a ChEI improve cerebral autoregulation?